Group for Innovative Cancer TreatmentDivision of Supportive Care Research
In the Division of Supportive Care Research Laboratory, we are trying to develop novel compounds for 1) analgesics for intolerable and morphine-resistant severe pain, and 2) reducing of side effects of chemotherapy and symptoms of cancer cachexia. Further, translational research from innovative seeds to first-in-human exploratory clinical trials is our main focus in the laboratory. Alternatively, development of such drug by drug repositioning is also conducted for improvement of quality of life(QOL)in cancer patients.
We are now collaborating with several universities and companies to proceed above activities. We also call our next collaborators to develop novel compounds related to improve QOL in cancer patients. If you have any questions, please contact "yuezono●ncc.go.jp（●を＠に差し替えてください）".
Project Research Assistant
- Support of projects regarding innovation of novel compounds in supportive and palliative care fields
- First-in-human, second and third clinical trials to develop a novel analgesic for oral mucositis in cancer patients
- Development of novel compounds for the inhibition of platelet-activating factor (PAF) signaling loop, the pathway causing progression of severe chronic pain
- Development of novel and specific agonists for m/d opioid hetero-dimerized receptors
- Development of compounds for the improvement of cancer cachexic symptoms: clinical application of ghrelin and des-acyl ghrelin for the inhibition of cardiac intoxication from chemotherapy and/or cancer cachexia
- Research of Japanese kampo medicines to improve (QOL) in cancer patients
See also Research Projects.
See also Publications.
Division of Supportive Care Research, Exploratory Oncology Research & Clinical Trial Center
(Division of Cancer Pathophysiology, Research Institute)
Telephone: 03-3542-2511 (Ext: 3877)